|Articles|October 14, 2016

Multiple Imaging Modalities based on Eidon Technology

Giovanni Staurenghi, professor of Ophthalmology at the University of Milan speaks about OCT, infrared, and autofluorescence base images used in practice. He explains how using blu autofluorescence imaging speeds up flow in cleaning and helps in diagnosis.

Giovanni Staurenghi, professor of Ophthalmology at the University of Milan, speaks about OCT, infrared, and autofluorescence base images used in practice. He explains how using blu autofluorescence imaging speeds up flow in cleaning and helps in diagnosis.

Back to Eye-to-Eye Innovation Series

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Multiple Imaging Modalities based on Eidon Technology

Related Content

FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)

Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy

Recognizing biomarkers of Alzheimer Disease using OCTA

Midyear cataract check-in: What 2026 has brought to the OR and beyond

Beyond the Walls: Leading with love, loyalty, and a team first philosophy with Vance Thompson, MD

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Retina Updates in Montréal

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy

FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)

Recognizing biomarkers of Alzheimer Disease using OCTA

Midyear cataract check-in: What 2026 has brought to the OR and beyond

Durability With Aflibercept 8 mg in Retinal Vascular Diseases